UniPharma Co., Ltd.
UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. It provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and f… Read more
Market Cap & Net Worth: UniPharma Co., Ltd. (6621)
UniPharma Co., Ltd. (TWO:6621) has a market capitalization of $14.11 Million (NT$466.84 Million) as of March 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #28115 globally and #1775 in its home market, demonstrating a 6.48% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying UniPharma Co., Ltd.'s stock price NT$13.15 by its total outstanding shares 35501000 (35.50 Million).
UniPharma Co., Ltd. Market Cap History: 2026 to 2026
UniPharma Co., Ltd.'s market capitalization history from 2026 to 2026. Data shows growth from $14.11 Million to $14.11 Million (0.00% CAGR).
UniPharma Co., Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how UniPharma Co., Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6621 by Market Capitalization
Companies near UniPharma Co., Ltd. in the global market cap rankings as of March 18, 2026.
Key companies related to UniPharma Co., Ltd. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
UniPharma Co., Ltd. Historical Marketcap From 2026 to 2026
Between 2026 and today, UniPharma Co., Ltd.'s market cap moved from $14.11 Million to $ 14.11 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$14.11 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of UniPharma Co., Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.11 Million USD |
| MoneyControl | $14.11 Million USD |
| MarketWatch | $14.11 Million USD |
| marketcap.company | $14.11 Million USD |
| Reuters | $14.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.